MD Mark I. Evans (Charlotte B. Failing Professor and Vice Chairman), MD Roderick F. Hume Jr, MD Yuval Yaron, MD Ralph L. Kramer (Instructor), MD Mark P. Johnson (Assistant Professor)
{"title":"10 Multifetal pregnancy reduction","authors":"MD Mark I. Evans (Charlotte B. Failing Professor and Vice Chairman), MD Roderick F. Hume Jr, MD Yuval Yaron, MD Ralph L. Kramer (Instructor), MD Mark P. Johnson (Assistant Professor)","doi":"10.1016/S0950-3552(98)80045-X","DOIUrl":null,"url":null,"abstract":"<div><p>Multifetal pregnancy reduction (MFPR) has become a mainstay of infertility therapy as its development has allowed physicians to become more aggressive in treating patients resistant to more conservative therapies. Over the course of the past decade, MFPR has become practised in a limited number of tertiary specialty centres, which have improved its performance and very substantially lowered its risks. The majority of physicians performing MFPR employ a transabdominal needle injection of potassium chloride into the fetal thorax. Risks for pregnancy losses of patients starting with triplets and/or quadruplets reduced to twins have improved over the past decade and are not substantially different from those in patients whose pregnancy began as twins. There have been no substantiated risks of coagulopathies or damage to surviving fetuses.</p></div>","PeriodicalId":77031,"journal":{"name":"Bailliere's clinical obstetrics and gynaecology","volume":"12 1","pages":"Pages 147-159"},"PeriodicalIF":0.0000,"publicationDate":"1998-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-3552(98)80045-X","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bailliere's clinical obstetrics and gynaecology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S095035529880045X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14
Abstract
Multifetal pregnancy reduction (MFPR) has become a mainstay of infertility therapy as its development has allowed physicians to become more aggressive in treating patients resistant to more conservative therapies. Over the course of the past decade, MFPR has become practised in a limited number of tertiary specialty centres, which have improved its performance and very substantially lowered its risks. The majority of physicians performing MFPR employ a transabdominal needle injection of potassium chloride into the fetal thorax. Risks for pregnancy losses of patients starting with triplets and/or quadruplets reduced to twins have improved over the past decade and are not substantially different from those in patients whose pregnancy began as twins. There have been no substantiated risks of coagulopathies or damage to surviving fetuses.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
